Welcome, Guest. Please login or register.
June 25, 2024, 10:48:28 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 73
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 47
Total: 47


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: AbbVie’s Glecaprevir/Pibrentasvir Cures Genotype 1 of Hep C at High Rates  (Read 6659 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
AbbVie’s investigational, once-daily, fixed-dose combination tablet glecaprevir/pibrentasvir, known as G/P, cured those with genotype 1 of hepatitis C virus (HCV) at high rates in a recent large trial, aidsmap reports. The pangenotypic treatment (meaning it works on all genotypes of hep C) will likely gain approval from the U.S. Food and Drug Administration (FDA) in 2017.
Researchers from the Phase III ENDURANCE-1 trial of 703 people with genotype 1 of hep C presented findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

For more information...

Offline elias

  • Member
  • Posts: 285
Very good news.

I'm still unclear if the "breakthrough" FDA approval track is for GT 1 only? Since the Phase III Endurance 2-4 series show amazing cure rates for GT 2, 3 and 4 as well. So hopefully, approval will be cross-genotype as well

The AbbVie  glecaprevir/pibrentasvir regimen seems on a par with even Gilead's pan-genotypic Epclusa . And similar in its low side effects. It's also promising as a "salvage" treatment for retreating previous DAA failures. Wonder if this competition might force lower prices in Gilead's drugs?
« Last Edit: January 09, 2017, 09:38:57 pm by elias »
Contracted HCV ~age 12
Diagnosed: September 2016 GT2b
F3 by Fibrosure: 0.66
Necroinflammat activity: A3 0.76
VL Sep. 12, 2016: 1.44 million/ Log: 6.157
AST:71/ ALT:114   Sept. 1, 2016 Before treatment
4 week after beginning  Epclusa:
AST 17/ALT 11
Began Epclusa:  October 22, 2016
End of Treatment [EOT]: January 13. 2017
SVR 12 April14-HCV Not Detected


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.